Gilgamesh Pharma

Psychedelic medicine developer

Gilgamesh Pharma, formerly Gilgamesh Pharmaceuticals, is a clinical-stage neuroscience biotech based in New York City. It develops investigational medicines for psychiatric and neurological conditions, including NMDA antagonists, neuroplastogens, an ibogaine analog, and a muscarinic agonist. In August 2025, AbbVie agreed to acquire bretisilocin, while Gilgamesh spun off its other programs into a new entity operating as Gilgamesh Pharma. Its candidates are investigational and are not available to buy.

Website

gilgameshpharmaceutical.com

Gilgamesh Pharma catalog

All products · Psychedelic medicine pipeline

Shop the Gilgamesh Pharma catalog

5 items across 1 shelf

Psychedelic medicine pipeline5 items

• Code not specified – M1/M4 muscarinic receptor agonistInvestigational
• GM-1020 – BlixeprodilInvestigational
• GM-2505 – BretisilocinInvestigational
• GM-3009 – Ibogaine analogInvestigational
• GM-5022 (code unconfirmed) – Non-hallucinogenic neuroplastogenInvestigational